Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

por Wray, Sibyl, Then Bergh, Florian, Wundes, Annette, Arnold, Douglas L., Drulovic, Jelena, Jasinska, Elzbieta, Bowen, James D., Negroski, Donald, Naismith, Robert T., Hunter, Samuel F., Gudesblatt, Mark, Chen, Hailu, Lyons, Jennifer, Shankar, Sai L., Kapadia, Shivani, Mendoza, Jason P., Singer, Barry A.
Publicado 2022

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

por Singer, Barry A, Arnold, Douglas L, Drulovic, Jelena, Freedman, Mark S, Gold, Ralf, Gudesblatt, Mark, Jasinska, Elzbieta, LaGanke, Christopher C, Naismith, Robert T, Negroski, Donald, Oh, Jiwon, Hernandez Perez, Miguel Angel, Selmaj, Krzysztof, Then Bergh, Florian, Wundes, Annette, Ziemssen, Tjalf, Castro-Borrero, Wanda, Chen, Hailu, Levin, Seth, Scaramozza, Matthew, Shankar, Sai L, Wang, Ting, Wray, Sibyl
Publicado 2023